OA10251A - Novel use of histamine h2 and/or h3 receptor agonist for the treatment of erectile disfunction - Google Patents

Novel use of histamine h2 and/or h3 receptor agonist for the treatment of erectile disfunction Download PDF

Info

Publication number
OA10251A
OA10251A OA60612A OA60612A OA10251A OA 10251 A OA10251 A OA 10251A OA 60612 A OA60612 A OA 60612A OA 60612 A OA60612 A OA 60612A OA 10251 A OA10251 A OA 10251A
Authority
OA
OAPI
Prior art keywords
agonist
histamine
agent
pyridyl
phentolamine
Prior art date
Application number
OA60612A
Other languages
English (en)
Inventor
Cesar Roberto Dias Nahoum
Original Assignee
Cesar Roberto Dias Nahoum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cesar Roberto Dias Nahoum filed Critical Cesar Roberto Dias Nahoum
Publication of OA10251A publication Critical patent/OA10251A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
OA60612A 1992-08-21 1995-02-16 Novel use of histamine h2 and/or h3 receptor agonist for the treatment of erectile disfunction OA10251A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR929203277A BR9203277A (pt) 1992-08-21 1992-08-21 Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao

Publications (1)

Publication Number Publication Date
OA10251A true OA10251A (en) 1997-10-07

Family

ID=4054796

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60612A OA10251A (en) 1992-08-21 1995-02-16 Novel use of histamine h2 and/or h3 receptor agonist for the treatment of erectile disfunction

Country Status (13)

Country Link
US (1) US5908853A (de)
EP (1) EP0655914B1 (de)
JP (1) JP2002510277A (de)
KR (1) KR100331754B1 (de)
AT (1) ATE233091T1 (de)
BR (1) BR9203277A (de)
CA (1) CA2142875A1 (de)
DE (1) DE69332713D1 (de)
NZ (1) NZ255278A (de)
OA (1) OA10251A (de)
TW (1) TW418090B (de)
WO (1) WO1994004120A2 (de)
ZA (1) ZA936118B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
GB9608408D0 (en) * 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
FR2748658B1 (fr) * 1996-05-15 2000-08-18 Biotec Centre Sa Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique
GR1002847B (el) * 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
DE19728103A1 (de) * 1997-07-02 1999-01-07 Winfried Dr Med Heinicke Pharmazeutisches Präparat zur Behandlung erektiler Dysfunktion sowie Injektionshilfe zur Injektion des Präparats
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
GB9802078D0 (en) * 1998-01-30 1998-03-25 Futura Medical Limited Preparation for treatment of erectile dysfunction
FR2774593B1 (fr) * 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
FR2786699B1 (fr) * 1998-12-02 2002-10-04 Philippe Gorny Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
DE60131644T2 (de) 2000-05-09 2008-10-30 Nitromed, Inc., Lexington Infrarotthermographie und behandlung von sexuellen dysfunktionen
CA2409592A1 (en) * 2000-05-22 2001-11-29 Illana Gozes Pharmceutical compositions comprising vip-related peptides for the treatment of sexual disorders
WO2002064212A1 (en) * 2001-02-13 2002-08-22 Cornell Research Foundation, Inc. Method and compositions for reducing cardiac dysfunctions with a selective histamine h3 receptor agonist
WO2003086372A2 (en) * 2002-04-10 2003-10-23 University Of Florida Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US7622844B1 (en) * 2003-12-30 2009-11-24 Hipercon, Llc Metal fiber brush interface conditioning
US20060013769A1 (en) * 2004-07-16 2006-01-19 Stephen Carter Transdermal drug delivery formulations and method of determining optimal amounts of vasodilators therein
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
US9034389B2 (en) * 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US20140121256A1 (en) * 2012-10-26 2014-05-01 Beech Tree Labs, Inc. Method of treating muscular weakness comprising administering a composition comprising an effective amount of histamine and/or serotonin
EP3439676B1 (de) 2016-04-04 2021-06-09 Omeza LLC Topische fischölzusammensetzung

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013659A (en) * 1973-07-13 1977-03-22 Smith Kline & French Laboratories Limited Certain n,n'-disubstituted guanidine compounds and their use
ZA771408B (en) * 1976-03-29 1978-04-26 Smith Kline French Lab Pharmaceutical compositions
JPS52156913A (en) * 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4293562A (en) * 1979-07-02 1981-10-06 Arnold Ritter Methods of obtaining anorexic effects using a combination of amphetamines and cimetidine
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DE3413371C1 (de) * 1984-04-09 1986-01-02 Esselte Pendaflex Corp., Garden City, N.Y. Etikett
US4840952A (en) * 1985-11-01 1989-06-20 Bristol-Myers Company Method for treatment of male impotence
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
EP0266968A3 (de) * 1986-11-03 1988-08-24 Gérard G. Cohen Gelierte Salbe mit einem Vasodilator
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
IT1221826B (it) * 1988-06-08 1990-07-12 Medico Harvey Srl Centro Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US4931445A (en) * 1988-10-06 1990-06-05 Irwin Goldstein Agents for treatment of male impotence
DE3913954A1 (de) * 1989-04-27 1990-10-31 Stief Georg Arzneimittel zur behandlung erektiler dysfunktionen
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
IT1252603B (it) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
IT1247678B (it) * 1990-05-31 1994-12-28 Alberto Reale Metodo per la cura dell'impotenza erettiva maschile
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
GB9012469D0 (en) * 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
ES2056337T3 (es) * 1990-11-08 1994-10-01 Boehringer Mannheim Gmbh Utilizacion de antagonistas de receptores de tromboxano-a2 para evitar modificaciones degenerativas en el tejido penil.
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions

Also Published As

Publication number Publication date
BR9203277A (pt) 1994-03-01
US5908853A (en) 1999-06-01
ATE233091T1 (de) 2003-03-15
WO1994004120A2 (en) 1994-03-03
WO1994004120A3 (en) 1994-05-26
KR950702823A (ko) 1995-08-23
JP2002510277A (ja) 2002-04-02
DE69332713D1 (de) 2003-04-03
AU678996B2 (en) 1997-06-19
NZ255278A (en) 1999-05-28
EP0655914A4 (de) 1998-04-22
KR100331754B1 (ko) 2002-10-04
EP0655914A1 (de) 1995-06-07
TW418090B (en) 2001-01-11
ZA936118B (en) 1995-04-20
AU4937193A (en) 1994-03-15
EP0655914B1 (de) 2003-02-26
CA2142875A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
US5952361A (en) Compositions
EP0655914B1 (de) Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen
US5059603A (en) Method and composition for treating impotence
AU710111B2 (en) Methods and formulations for modulating the human sexual response
US5492911A (en) Linsidomine for the treatment for erectile dysfunctions
AU2001259848B2 (en) Local anesthetic methods and kits
DE69415535T2 (de) Verfahren zur regulierung der sexuellen reaktion beim menschen
AU759825B2 (en) Combination effective for the treatment of impotence
KR20020073498A (ko) 남성 발기부전증을 치료하기 위한 프로스타글란딘 조성물및 방법
US6589990B1 (en) Methods and compositions for misoprostol compound treatment of erectile dysfunction
CZ280446B6 (cs) Prostředek pro podání mužům trpícím impotencí
US5583144A (en) Methods for treating erectile impotence
NZ238339A (en) Use of doxazosin, amlodipine, or u.k.-52,046 for treating erectile impotence in human males
KR20010080053A (ko) 말초 작용 항소양 아편제
JPH04504856A (ja) 勃起障害治療のための医薬組成物および勃起障害の治療方法
JP4377585B2 (ja) 射精遅延の方法
AU749703B2 (en) Combination therapy for modulating the human sexual response
US5177070A (en) Method of treating physiologic male erectile impotence
JPH02326B2 (de)
EP0618798B1 (de) Pyridylguanidine verbindungen zur behandlung von erektionsstörungen
US20040110843A1 (en) Methods of treatment of male erectile dysfunction
AU678996C (en) Method of treating sexual dysfunction in animals with an H agonist
JP2020523300A (ja) キサンチン又はキサンチン誘導体の医薬製剤、及びその使用
AU2003273291A1 (en) Methods of treatment of male erectile dysfuntion
FR2748658A1 (fr) Utilisation de composes du type &#34;alpha-bloquants&#34; notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique